NEW YORK (GenomeWeb) – Meridian Bioscience today reported its fiscal first quarter revenues decreased approximately 2 percent due primarily to volume and pricing pressures in its molecular and gastrointestinal product lines. The firm also slightly lowered its 2019 guidance.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.